| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | OSU-03012 | GDSC1000 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | Gemcitabine | GDSC1000 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | IPR-456 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | BRD-K33199242 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.0098 | 0.8 |
| mRNA | MST-312 | CTRPv2 | pan-cancer | AAC | -0.0099 | 0.8 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.014 | 0.8 |
| mRNA | GDC-0449 | GDSC1000 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | BRD-K34485477 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.8 |